BioMarin Pharmaceuticals BMRN Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues by Product | |||||
| ALDURAZYME | $208.51M+13.4% | $183.89M+40.1% | $131.25M+2.2% | $128.42M+4.6% | |
| BRINEURA | $186.4M+10.2% | $169.08M+4.4% | $161.89M+4.9% | $154.33M+20.5% | |
| KUVAN | $99.53M-17.7% | $120.9M-33.1% | $180.77M-20.6% | $227.58M-20.4% | |
| NAGLAZYME | $485.4M+1.2% | $479.58M+14.1% | $420.29M-5.3% | $443.79M+16.7% | |
| PALYNZIQ | $433.31M+22.0% | $355.05M+16.8% | $303.92M+19.2% | $255.03M+7.4% | |
| ROCTAVIAN | $35.64M+36.7% | $26.07M+647% | $3.49M— | —— | |
| Royalty and other revenues | $53.49M+20.3% | $44.47M-4.8% | $46.69M-13.6% | $54.01M-14.0% | |
| VIMIZIM | $792.05M+7.1% | $739.78M+5.5% | $701.05M+5.6% | $663.74M+6.5% | |
| VOXZOGO | $926.92M+26.1% | $735.09M+56.4% | $469.88M+178% | $169.13M+2,789% | |
| R&D by Product | |||||
| Later-stage clinical programs | $308.33M+175% | $112.18M+79.2% | $62.6M-47.4% | $119.02M— | |
| Marketed products | $229.89M-19.5% | $285.58M-1.9% | $291.09M+34.3% | $216.68M— | |
| Research and early pipeline | $383.71M-11.6% | $434.02M+10.4% | $393.08M+25.2% | $313.92M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BioMarin Pharmaceuticals break its business down?
- BioMarin Pharmaceuticals (BMRN) reports total revenues by product across 9 parts — ALDURAZYME, BRINEURA, KUVAN, NAGLAZYME and PALYNZIQ. Each is extracted from the segment footnotes and tracked over time.
- Where does BioMarin Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioMarin Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
